Ricevi le ultime notizie sulle azioni Insmed con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di INSM

Ultime notizie per

Insmed

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Jim Cramer- AI Is Bigger Than Rate Cuts

Long Ideas

News

Markets

Media

Trading Ideas

INSM

OUST

PAAS

PSNL

TSLA

Un&#39;azione mineraria brilla sul mercato, ma il noto analista frena gli entusiasmi. Non sempre un rialzo è un buon segnale d&#39;acquisto.

Questo titolo sale del 5%, ma per Jim Cramer non è quello giusto

Insmed Inc

Offerings

Press Releases

Insmed Announces Pricing of $750 Million Public Offering of Common Stock

Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025

Opinion

Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas

OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee

Earnings

Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

Biotech at a Pivotal Moment: Four Stocks Defining The Transformation (MDCX, IOBT, INSM, RNA)

Insmed To Present at September Investor Conferences

Bloomberg 500 (B500) Index Adds Sixteen Securities Following Semi-Annual Reconstitution

AFRM

AKAM

ALAB

AMTM

AVTR

CYBR

ENTG

EPAM

IMNM

IOBT

KURA

LINE

MDCX

NTNX

RKLB

RPTX

RVTY

SNDK

SNGX

SOFI

SWKS

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical

BioNTech

Caris Life Sciences

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeOne Medicines Ltd. - American Depositary Shares

BeOne Medicines

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Morgan Stanley

JP Morgan

Truist Securities

Stifel

Comments

Insmed Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO